DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for lipodystrophy — screening already-approved drugs against its 7-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLipodystrophy maps to a 7-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for lipodystrophy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
peroxisome proliferator activated receptor gamma (PPARG) — PPARG is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 9cisdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3DZY · 3.1 Å · ligand (9cis)-retinoic acid (9CR). Experimental structure, not a prediction.
What the evidence adds up to
A 2006 study of 245 HIV patients with lipodystrophy who attended a metabolic clinic and received a multidisciplinary approach including medical therapy, exercise, and surgery reported significant improvements in waist-to-hip ratio, waist circumference, and cheek dermal thickness over 48 weeks. Glucose, HOMA-IR, total cholesterol, and APO B also improved. However, improvements in fat and lean regional mass measured by DEXA were not significant, and CT changes in visceral and subcutaneous adipose tissue were not clearly quantified as significant. Aesthetic satisfaction improved subjectively.
A 2009 review of HIV-associated lipodystrophy concluded that most studied treatments produce minimal or modest effects that are not sustained when therapy is stopped. It stated that treatment strategies must differ for lipoatrophy versus central fat accumulation, and that managing metabolic abnormalities like insulin resistance and hyperlipidaemia is complicated by worse response and drug-drug interactions with antiretrovirals. The review called for further research into combination therapies and underlying mechanisms.
A 2025 review of lipodystrophy syndromes, which include both inherited and acquired forms, stated that there is currently no definitive cure and that clinical management remains symptomatic. It identified dietary modification, exercise, lifestyle management, and metreleptin therapy as the mainstay of treatment, with conventional therapies used only for specific complications. The review noted that novel interventions are under investigation but did not report any positive efficacy data from those investigations.
What is still missing are treatments that produce durable effects, clear evidence for combination therapies, and therapies that address the underlying mechanisms of adipose tissue loss rather than just managing metabolic complications. No trial has yet shown reversal of fat loss or accumulation that persists after treatment ends, and patient stratification by lipodystrophy subtype remains poorly integrated into trial design.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
HIV Clinical Trials · 2006 · 57 citations
Multidisciplinary Approach to the Treatment of Metabolic and Morphologic Alterations of HIV-Related Lipodystrophy
AbstractBACKGROUND: Treatment for metabolic and morphologic alterations in HIV-related lipodystrophy include medical therapy, physical exercise, and surgical interventions. METHOD: We assessed the efficacy and safety of a comprehensive multidisciplinary approach for treating morphological and metabolic alterations of the lipodystrophy syndrome in consecutive patients attending the Metabolic Clinic (MC) of the University of Modena and Reggio Emilia who had at least 2 evaluations over a 48-week period. 245 patients were evaluated: 143 (62.4%) were men, 74 (36.1%) presented with lipoatrophy, 10 (4.9%) with fat accumulation, 93 (45%) with mixed forms, 24 (11.3%) had hypercholesterolemia (LDL >160 mg/dL), 87 (38%) had hypertriglyceridemia (TG >150 mg/dL), 13 (5.7%) had diabetes (glucose >126 mg/dL), and 78 (44%) had insulin resistance (HOMA-IR >4). RESULTS: At follow-up, a significant improvement was observed in both objective and subjective variables. Anthropometric improvement was observed in waist to hip ratio, waist circumference, and right and left cheek dermal thickness measurements. A nonsignificant improvement was observed in fat and lean regional mass by DEXA; CT showed improvement in visceral and subcutaneous adipose tissue. Glucose, HOMA-IR, total cholesterol, and APO B improved. Subjective variables improved in aesthetic satisfaction. CONCLUSION: We conclude that the medical and surgical interventions proposed in this multidisciplinary therapeutic approach are efficacious and safe in the management of lipodystrophy.
Current Opinion in Lipidology · 2009 · 10 citations
Clinical management of HIV-associated lipodystrophy
AbstractPURPOSE OF REVIEW: Lipodystrophy or fat re-distribution, and its associated metabolic abnormalities, are common in HIV patients. The pathogenesis is multifactorial. This article provides an update on the latest findings of the different clinical management strategies that have been utilized in patients with lipodystrophy. RECENT FINDINGS: Treatment strategies need to be different in those patients with lipoatrophy when compared with patients with central fat accumulation (lipohypertrophy). Most of the treatments studied have produced minimal or modest effects, which are not sustained when the therapy is discontinued. The treatment of associated metabolic abnormalities such as insulin resistance and hyperlipidemia should have similar goals to that in the non-HIV population, but is complicated by the fact that response may be worse and there is a need to consider drug-drug interactions with the antiretrovirals. SUMMARY: Multiple complex strategies will need to be utilized in these patients to treat the different features seen in lipodystrophy in order to reduce their long-term cardiovascular risk. Further research is also needed to evaluate combination therapies and to identify the underlying mechanisms in order to develop novel therapies for the future.
Expert Review of Endocrinology & Metabolism · 2025 · 2 citations · open access
Advances of pharmacological therapies in lipodystrophy syndromes: current evidence and future directions
AbstractINTRODUCTION: Lipodystrophy syndromes are a heterogeneous group of rare disorders characterized by partial or generalized loss of adipose tissue, which may be either inherited or acquired. Loss of adipose tissue in typical storage sites starting from birth or later in life, combined with abnormal fat accumulation in other organs, contributes to multiple metabolic complications. There is currently no definitive cure available for lipodystrophy syndromes, and clinical management remains symptomatic. AREAS COVERED: For this review, available databases were searched to identify publications and studies on current and emerging therapies to discuss the management of lipodystrophy syndromes. Dietary modification, exercise, lifestyle management, and metreleptin therapy are the mainstay of treatment, while conventional therapies are used to target specific complications. Novel interventions are under investigation to address unmet clinical needs. EXPERT OPINION: There is currently no cure for lipodystrophy syndromes. Emerging therapies are being investigated to expand therapeutic options and improve long-term outcomes of this complex disorder.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
